Log in to your account:
Lilly's (LLY) CYRAMZA Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving PSFl in First-Line Treatment of Patients with Metastatic EGFR-Mutated NSCLC
March 12, 2019 6:46 AM
Eli Lilly and Company (NYSE: LLY) today announced that its Phase 3 RELAY study of CYRAMZA® (ramucirumab) met its primary ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Hot FDA News
Lilly's CYRAMZA® (ramucirumab) Phase 3 RELAY Trial Met Primary Endpoint, Significantly Improving Progression-Free Survival in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small C
March 12, 2019 6:45 AM